贝瑞基因(000710) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥334,982,971.78, a decrease of 9.46% compared to ¥369,973,449.87 in the same period last year[7] - The net profit attributable to shareholders for Q1 2021 was ¥21,242,485.44, down 65.95% from ¥62,393,298.10 in the previous year[7] - Basic earnings per share for Q1 2021 were ¥0.0599, a decline of 66.08% from ¥0.1766 in the previous year[7] - The estimated net profit for the period from the beginning of the year to the next reporting period is projected to be between 40 million and 60 million yuan, representing a decrease of 65.95% compared to the same period last year, which was 117.47 million yuan[24] - Basic earnings per share are expected to decline to between 0.1128 and 0.1692 yuan per share, down 65.95% from 0.3313 yuan per share in the same period last year[24] - Total comprehensive income for the first quarter was CNY 20,948,311.58, compared to CNY 60,048,341.05 in the previous period[45] Cash Flow and Liquidity - The net cash flow from operating activities was -¥106,619,684.26, an improvement of 29.92% compared to -¥152,146,155.23 in the same period last year[7] - Cash and cash equivalents decreased by 34.14% to 414.46 million yuan, primarily due to payments for raw materials and fixed asset purchases[16] - The company received 22.47 million yuan in cash related to operating activities, a 1719.10% increase, mainly from the recovery of performance guarantees[16] - Cash flow from operating activities generated a net outflow of CNY 106,619,684.26, compared to a net outflow of CNY 152,146,155.23 in the previous period[52] - Cash and cash equivalents at the end of the period totaled CNY 414,462,361.65, down from CNY 629,308,298.94 at the beginning of the period[53] - The ending balance of cash and cash equivalents was 1,840,630.30 yuan, down from 4,288,037.44 yuan in the previous period[56] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,175,283,029.22, a decrease of 2.12% from ¥3,243,969,209.24 at the end of the previous year[7] - The company's total liabilities as of March 31, 2021, were approximately 731.64 million yuan, down from approximately 821.52 million yuan at the end of 2020[36] - Total liabilities decreased to CNY 109,134,746.38 from CNY 148,113,528.38[40] - The equity attributable to shareholders of the parent company was CNY 4,527,857,606.37, down from CNY 4,563,057,644.73[40] - The company's retained earnings stood at 1,052,858,965.48 yuan, contributing to the total equity attributable to shareholders of 2,388,438,682.50 yuan[62] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,030[10] - The largest shareholder, Gao Yang, held 13.89% of the shares, amounting to 49,260,572 shares, with 36,945,429 shares pledged[10] - The company repurchased a total of 3,907,400 shares, accounting for approximately 1.1018% of the total share capital, with a total transaction amount of 160.39 million yuan[19] Government and Regulatory Matters - The company received government subsidies amounting to ¥422,389.51 during the reporting period[8] - The company has terminated the review of its non-public offering of A-shares by the China Securities Regulatory Commission, which did not significantly impact its financial status[17] - The company has revised its employee stock ownership plan to utilize 3.9 million repurchased shares, aligning with its long-term strategic development[20] Future Outlook and Strategy - The company anticipates a slowdown in the growth rate of medical product and service testing due to a continuous decline in birth rates, leading to a decrease in overall gross profit margin[24] - The company plans to accelerate product iteration and upgrade to improve the proportion of high-margin products and services, aiming to enhance overall gross profit margin levels[24] - Recent central bank statements on fertility issues are expected to stimulate market demand for prenatal testing products, which the company aims to leverage through its first-mover and technological advantages[24] Research and Development - Research and development expenses for Q1 2021 were CNY 31,015,909.78, compared to CNY 29,580,787.68 in the previous year[43] - The company reported an investment loss of CNY 10,069,473.09, an improvement from a loss of CNY 13,836,212.07 in the previous period[43] Miscellaneous - The first quarter report for 2021 was not audited, indicating potential limitations in financial assurance[67] - The company has not disclosed any new product developments or market expansion strategies in the current report[68] - There were no adjustments made for the new leasing standards in the financial statements[66]